Cargando…

Higher Risk of Hypoglycemia with Glimepiride Versus Vildagliptin in Patients with Type 2 Diabetes is not Driven by High Doses of Glimepiride: Divergent Patient Susceptibilities?

INTRODUCTION: In a previously published study, vildagliptin showed a reduced risk of hypoglycemia versus glimepiride as add-on therapy to metformin at similar efficacy. Glimepiride was titrated from a starting dose of 2 mg/day to a maximum dose of 6 mg/day. It is usually assumed that the increased h...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ahrén, Bo, Foley, James Edward, Dejager, Sylvie, Akacha, Mouna, Shao, Qing, Heimann, Guenter, Dworak, Markus, Schweizer, Anja
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Healthcare 2014
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4269641/ https://www.ncbi.nlm.nih.gov/pubmed/25230877 http://dx.doi.org/10.1007/s13300-014-0082-y

Ejemplares similares

Changes in Prandial Glucagon Levels After a 2-Year Treatment With Vildagliptin or Glimepiride in Patients With Type 2 Diabetes Inadequately Controlled With Metformin Monotherapy
por: Ahrén, Bo, et al.
Publicado: (2010)

Comparison of Vildagliptin-Metformin and Glimepiride-Metformin Treatments in Type 2 Diabetic Patients
por: Jeon, Hyun Jeong, et al.
Publicado: (2011)

Minimizing the risk of hypoglycemia with vildagliptin: Clinical experience, mechanistic basis, and importance in type 2 diabetes management
por: Dejager, Sylvie, et al.
Publicado: (2011)

Evidence to support the use of vildagliptin monotherapy in the treatment of type 2 diabetes mellitus
por: Dejager, Sylvie, et al.
Publicado: (2012)

Comparison of Safety and Efficacy of Glimepiride-Metformin and Vildagliptin- Metformin Treatment in Newly Diagnosed Type 2 Diabetic Patients
por: Kumar, Surendra
Publicado: (2021)

Experience with Vildagliptin in Patients ≥75 Years with Type 2 Diabetes and Moderate or Severe Renal Impairment
por: Schweizer, Anja, et al.
Publicado: (2013)

Impact of Insulin Resistance, Body Mass Index, Disease Duration, and Duration of Metformin Use on the Efficacy of Vildagliptin
por: Schweizer, Anja, et al.
Publicado: (2012)

Vildagliptin reduces plasma stromal cell‐derived factor‐1α in patients with type 2 diabetes compared with glimepiride
por: Park, Kyeong Seon, et al.
Publicado: (2016)

Cost effectiveness of vildagliptin versus glimepiride as add-on treatment to metformin for the treatment of diabetes mellitus type 2 patients in Greece
por: Kousoulakou, Hara, et al.
Publicado: (2017)

Combination treatment in the management of type 2 diabetes: focus on vildagliptin and metformin as a single tablet
por: Halimi, Serge, et al.
Publicado: (2008)

Optimal Candidates for the Switch from Glimepiride to Sitagliptin to Reduce Hypoglycemia in Patients with Type 2 Diabetes Mellitus
por: Kim, Hyun Min, et al.
Publicado: (2015)

Comparison of the efficacy of sitagliptin and glimepiride dose‐up in Japanese patients with type 2 diabetes poorly controlled by sitagliptin and glimepiride in combination
por: Shimoda, Seiya, et al.
Publicado: (2013)

Assessing the general safety and tolerability of vildagliptin: value of pooled analyses from a large safety database versus evaluation of individual studies
por: Schweizer, Anja, et al.
Publicado: (2011)

Formulation and characterization of orodispersible tablet of glimepiride
por: Kinani, Ahmad AB Yosef, et al.
Publicado: (2022)

Clinical evidence and mechanistic basis for vildagliptin’s effect in combination with insulin
por: Schweizer, Anja, et al.
Publicado: (2013)

Glimepiride: evidence-based facts, trends, and observations
por: Basit, Abdul, et al.
Publicado: (2012)

Formulation and Evaluation of New Glimepiride Sublingual Tablets
por: Al-Madhagi, Wafa, et al.
Publicado: (2017)

Erratum: Formulation and characterization of orodispersible tablet of glimepiride
Publicado: (2023)

Insight into the Formation of Glimepiride Nanocrystals by Wet Media Milling
por: Medarević, Djordje, et al.
Publicado: (2020)

Glimepiride monotherapy versus combination of glimepiride and linagliptin therapy in patients with HNF1A-diabetes: a protocol for a randomised, double-blinded, placebo-controlled trial
por: Sidelmann Christensen, Alexander, et al.
Publicado: (2018)

Glimepiride Administered in Chow Reversibly Impairs Glucose Tolerance in Mice
por: Niedowicz, Dana M., et al.
Publicado: (2018)

The Anti-Breast Cancer Effect and Mechanism of Glimepiride-Metformin Adduct
por: Long, Liangyuan, et al.
Publicado: (2020)

Cardiovascular safety of Glimepiride: An indirect comparison from CAROLINA and CARMELINA
por: Ghosh, Sujoy, et al.
Publicado: (2020)

CARdiovascular Outcome study of LINAgliptin versus glimepiride in patients with T2D trial
por: Nath, Baishali, et al.
Publicado: (2020)

Increased Frequency of Severe Hypoglycemia with the Modified-Release Gliclazide Compared to Glimepiride in Diabetic Older Adults; Propensity Score-Adjusted Analysis
por: Fouad Algendy, Ahmed, et al.
Publicado: (2022)

Four-Point Preprandial Self-Monitoring of Blood Glucose for the Assessment of Glycemic Control and Variability in Patients with Type 2 Diabetes Treated with Insulin and Vildagliptin
por: Tura, Andrea, et al.
Publicado: (2015)

A review of pioglitazone HCL and glimepiride in the treatment of type 2 diabetes
por: Dorkhan, Mozhgan, et al.
Publicado: (2007)

Dissolution enhancement of glimepiride using modified gum karaya as a carrier
por: Nagpal, Manju, et al.
Publicado: (2012)

Glimepiride reduces CD14 expression and cytokine secretion from macrophages
por: Ingham, Victoria, et al.
Publicado: (2014)

Glimepiride and Metformin Combinations in Diabetes Comorbidities and Complications: Real-World Evidence
por: Sahay, Rakesh Kumar, et al.
Publicado: (2020)

Pharmacokinetic/Pharmacodynamic Interactions Between Evogliptin and Glimepiride in Healthy Male Subjects
por: Yoo, Hyounggyoon, et al.
Publicado: (2020)

Pharmacodynamic and pharmacokinetic interaction of losartan with glimepiride-metformin combination in rats and rabbits
por: Nagaraju, Beere, et al.
Publicado: (2021)

Pharmacometabolomic profiles in type 2 diabetic subjects treated with liraglutide or glimepiride
por: Jendle, J., et al.
Publicado: (2021)

Accidental exposure to glimepiride from adulterated medication resulting in severe hypoglycaemia
por: Hayes, Annabelle G, et al.
Publicado: (2022)

Treatment satisfaction in type 2 diabetes patients taking empagliflozin compared with patients taking glimepiride
por: Chirila, Costel, et al.
Publicado: (2015)

Long-term outcomes in patients with type 2 diabetes receiving glimepiride combined with liraglutide or rosiglitazone
por: Sullivan, Sean D, et al.
Publicado: (2009)

Efficacy of Combination Therapy With Sitagliptin and Low-Dose Glimepiride in Japanese Patients With Type 2 Diabetes
por: Ishii, Hiroaki, et al.
Publicado: (2014)

Effect of sitagliptin and glimepiride on C-reactive protein (CRP) in overweight Type-2 diabetic patients
por: Hussain, Mazhar, et al.
Publicado: (2019)

Glimepiride-induced cholestasis in a man with diabetes mellitus: a case report
por: Omar, Hesham, et al.
Publicado: (2009)

Mechanistic analysis of Zein nanoparticles/PLGA triblock in situ forming implants for glimepiride
por: Ahmed, Osama Abdelhakim Aly, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_8npl891gsu25rel51g1675921e